Concord Biotech IPO GMP History
Concord Biotech IPO has been listed on August 18, 2023 at a listing price of ₹900.05, against the issue price of ₹741 — a gain of ₹159.05 (+21.46%). The GMP peaked at ₹300 on 31 July 2023 and reached a low of ₹0.01 on 4 August 2023. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Concord Biotech IPO raised ₹1550.52 Cr. through its IPO at a price band of ₹705 to ₹741 per share, with a lot size of 20 shares. The IPO was open for subscription from 04 Aug 2023 to 08 Aug 2023.
GMP trend
Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 10 Nov, 6:04 PM IST.
Day-wise GMP
The last reading of each day, newest first. Arrows compare with the previous day.
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 08 Aug 2023 | ₹ 67.67 | ▲ | 9% | — | — |
| 07 Aug 2023 | ₹ 1.61 | ▲ | -- | — | — |
| 04 Aug 2023 | ₹ 0.01 | ▼ | -- | — | — |
| 31 Jul 2023 | ₹ 300 | — | 40% | — | — |
Concord Biotech IPO dates
Key dates from opening to listing. Today is 17 November.
- Open 04 Aug 2023
- Close 08 Aug 2023
- Allotment 11 Aug 2023
- Refund/credit 14 Aug 2023
- Listing 18 Aug 2023
Concord Biotech IPO actual listing price
How the grey market's final call compared with the listing-day open.
| Issue price | ₹741 |
|---|---|
| GMP-based estimate (pre-listing) | ₹808 (+9%) |
| Listing gain / loss | +₹159.05 per share |
| Listing date | 18 Aug, 2023 |
| Actual listing price | ₹900.05 (+21.46%) |
Is Concord Biotech IPO GMP reliable?
Grey market premium for Concord Biotech IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- 04Cross-check before acting: Review the Concord Biotech IPO full review for a fundamentals-based assessment before making any grey market trades.
Concord Biotech IPO Kostak rate explained
Two ways the grey market trades an IPO application before listing.
The Kostak rate for Concord Biotech IPO was not available during the subscription period. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not available for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Concord Biotech IPO
Concord Biotech Limited was incorporated in 1984 and is based in India. As per the F&S report, it is one of the leading global developers and makers of select fermentation-based APIs across immunosuppressants and oncology by volume market share in 2022.
It makes APIs through fermentation and semi-synthetic processes, and also makes finished formulations. Its therapy areas include immunosuppressants, anti-bacterials, oncology and antifungals.
On 31 March 2023 it had 23 APIs and 77 approved products for formulations, and over 200 customers in over 70 countries, including the USA, Europe and Japan.
The IPO was Rs 1,550.52 crore and was entirely an offer for sale by Helix Investment Holdings, which sold its whole 20% stake. The company and the promoters received none of the money.
Frequently asked
What is the GMP of Concord Biotech IPO?
The current Grey Market Premium (GMP) of Concord Biotech IPO is ₹ 67.67.
What is the Kostak Price of Concord Biotech IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Concord Biotech IPO is not available.
What is the Subject to Sauda Price of Concord Biotech IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is not available.
What was the actual listing price of Concord Biotech IPO?
Concord Biotech IPO listed on August 18, 2023 at ₹900.05, against the issue price of ₹741 — a gain of +21.46%.
How did the GMP of Concord Biotech IPO trend before listing?
The GMP of Concord Biotech IPO was rising in its final days before listing. The GMP peaked at ₹300 on 31 July 2023. View the day-wise table above for the complete GMP history.
Explore Concord Biotech IPO further
The grey market is one signal. Read it alongside the demand, the reviews and the filings before you decide.
It has listed — go back to the fundamentals.
Category-wise demand from QIB, NII and retail investors, updated through the day.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
The grey market called it. Now check the fundamentals.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.